

# Retrospective Observational non-interventional chart review study of patients with Pulmonary Arterial Hypertension (PAH) or Chronic Thromboembolic Pulmonary Hypertension (CTEPH) in Finland (FINPAH)

**First published:** 28/06/2021

**Last updated:** 23/04/2024

Study

Ongoing

## Administrative details

### EU PAS number

EUPAS41732

---

### Study ID

41733

---

### DARWIN EU® study

No

---

## Study countries

☐ Finland

---

## Study description

The study is an observational, retrospective, non-interventional patient chart review study, whose population is Finnish adult patients with a confirmed diagnosis of pulmonary arterial hypertension (PAH) or chronic thromboembolic pulmonary hypertension (CTEPH), or with specific therapy for PAH or CTEPH initiated at any time between years 2008-2019. The primary aim is to investigate the real-life patient characteristics, treatment patterns and clinical outcomes of PAH and CTEPH patients in Finland during years 2008-2020. Secondary aim of the study is to examine direct and indirect costs associated with PAH and CTEPH.

---

## Study status

Ongoing

# Research institutions and networks

## Institutions

[Helsinki University Hospital \(HYKS\)](#)

**First published:** 01/02/2024

**Last updated:** 01/02/2024

Institution

## Tampere University Hospital

☐ Finland

**First published:** 01/02/2024

**Last updated:** 01/02/2024

Institution

Educational Institution

Hospital/Clinic/Other health care facility

## University of Turku

**First published:** 01/02/2024

**Last updated:** 01/02/2024

Institution

Tampere University Hospital Tampere, Finland,  
Turku University Central Hospital Turku, Finland,  
Oulu University Hospital Oulu, Finland, Kuopio  
University Hospital Kuopio, Finland

## Contact details

### Study institution contact

Markku Pentikäinen studies@esior.fi

**Study contact**

[studies@esior.fi](mailto:studies@esior.fi)

**Primary lead investigator**

Markku Pentikäinen

**Primary lead investigator**

## Study timelines

**Date when funding contract was signed**

Actual: 10/02/2021

---

**Study start date**

Actual: 21/04/2021

---

**Date of final study report**

Planned: 30/09/2022

## Sources of funding

- Pharmaceutical company and other private sector

## More details on funding

Janssen-Cilag Oy

## Regulatory

**Was the study required by a regulatory body?**

No

---

**Is the study required by a Risk Management Plan (RMP)?**

Not applicable

## Methodological aspects

### Study type

### Study type list

**Study type:**

Non-interventional study

---

**Scope of the study:**

Disease epidemiology

Drug utilisation

Effectiveness study (incl. comparative)

**Main study objective:**

The primary aim is to investigate the real-life patient characteristics, treatment patterns and clinical outcomes of PAH and CTEPH patients in Finland

## Study Design

## Non-interventional study design

Cohort

Other

---

## Non-interventional study design, other

Observational, non-interventional retrospective patient chart review study

# Study drug and medical condition

## Medical condition to be studied

Pulmonary arterial hypertension

Pulmonary hypertension

# Population studied

## Age groups

Adults (18 to < 46 years)

Adults (46 to < 65 years)

Adults (65 to < 75 years)

Adults (75 to < 85 years)

Adults (85 years and over)

---

## Estimated number of subjects

450

# Study design details

## Outcomes

1. Patient characteristics and risk groups as defined by ESC/ERS risk assessment parameters. 2. Used treatments and treatment pathways (e.g. procedures, medication, posology, treatment duration, switch patterns or discontinuation incl. possible reason). Outcomes (e.g. annualized resource use) and treatment effects defined as comparing assessments at diagnosis of PAH (baseline) and at follow-ups (potential differentiation between ERAs as derived outcomes).

---

## Data analysis plan

Analysis will include basic statistical analysis methods aimed to describe the results. More advanced methods (e.g. multivariate modelling) may be used and subgroup analysis can be performed, if sample size and information collected is enough for such analysis. Reporting of all data is conditional of having enough observations (absolute minimum is 5 observations).

## Data management

### ENCePP Seal

The use of the ENCePP Seal has been discontinued since February 2025. The ENCePP Seal fields are retained in the display mode for transparency but are no longer maintained.

### Data sources

## **Data sources (types)**

Other

---

### **Data sources (types), other**

Routine secondary care electronic patient registry

## Use of a Common Data Model (CDM)

### **CDM mapping**

No

## Data quality specifications

### **Check conformance**

Unknown

---

### **Check completeness**

Unknown

---

### **Check stability**

Unknown

---

### **Check logical consistency**

Unknown

## Data characterisation

### **Data characterisation conducted**

No